EU starts real-time review of AstraZeneca COVID-19 antibody cocktail


Reuters | Updated: 14-10-2021 18:12 IST | Created: 14-10-2021 18:01 IST
EU starts real-time review of AstraZeneca COVID-19 antibody cocktail
Representative Image Image Credit: ANI

Europe's drug regulator said on Thursday it had started a real-time review of the antibody-based COVID-19 therapy developed by AstraZeneca, roughly a week after the Anglo-Swedish drugmaker sought emergency approval from U.S. authorities.

The decision to begin the assessment by the human medicines committee of the European Medicines Agency (EMA) was based on early results from clinical studies, the regulator said in a statement, without specifying when a conclusion was expected. The medicine, the first protective shot other than vaccines against COVID-19, has proven to work in the non-infected and was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.

"EMA will evaluate more data on the quality, safety, and effectiveness of the medicine as they become available," the watchdog said, adding that the rolling review would continue until AstraZeneca submits a formal application for approval.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback